Swimming the Catalan coast to raise funds for TRICALS

To raise funds for TRICALS, Daniel Rossinés has taken on an epic…

Words Lucie van Leeuwen.Published October 1, 2020
Swimming the Catalan coast to raise funds for TRICALS

To raise funds for TRICALS, Daniel Rossinés has taken on an epic challenge. In 24 consecutive days he is swimming the entire Catalan coast: 400 km. He started in Portbou (Girona) on the 17th of September and will finish in Les Cases d’Alcanar (Tarragona).

Daniel Rossinés started to raise funds for ALS research in 2014 when he learned that his good friend was diagnosed with ALS. He then decided to combine his love for open water swimming with his skills in business management to organise fundraising challenges. For his next brave effort, the ‘Upside Down Challenge’, he swims along the Catalan coast from north to south. Other people have also joined him at several stages of his journey so far.

Besides raising money, this action also aims to raise more awareness about ALS. His initiative has already received a lot of media attention in Spain and is sponsored by former footballer and coach Juan Carlos Unzué, who announced last June that he suffers from ALS. The children of the sportsman have even accompanied Daniel Rossinés on one day of his swim.

At this moment, Daniel Rossinés has swum over 200 km and raised more than €48.000. The goal is to raise €200.000 – €1 for every swimming stroke. All the money raised will be managed by Fundación Luzón and goes towards research activities of TRICALS. We are very grateful for this courageous initiative and wish Daniel all the strength to face the second half of his journey ahead. We thank him, and everyone who donated or joined him in this challenge, for their support in our mission to speed up the development of new therapies for people living with ALS.

Donations can be made by clicking this link (in Spanish).

Updates of the project are regularly shared on the Upside Down Challenge Instagram account.


Share

Related news

Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Amylyx withdraws RELYVRIO/AMX0035 from U.S. and Canadian markets
Yesterday, the pharmaceutical company Amylyx announced that they are withdrawing the drug […]
Results of TUDCA-study: No effect of investigated compound
Results of TUDCA-study: No effect of investigated compound
The TUDCA-ALS consortium has announced the first findings of the TUDCA study, […]
Amylyx: no effect after analyzing phase 3 study
Amylyx: no effect after analyzing phase 3 study
The pharmaceutical company Amylyx announced the first results of the PHOENIX study. […]
Tofersen receives positive opinion from CHMP (EMA)
Tofersen receives positive opinion from CHMP (EMA)
The Committe of Medicinal Products for Human Use (CHMP) of the European […]